InvestorTalk Alert: Brent Willis From Voyageur Pharmaceuticals Ltd. To Host on Tuesday, March 31, 2026

Key Takeaways

• InvestorTalk with CEO Brent Willis scheduled March 31, 2026
• 132k tonnes of 98.8% pure barium ready H2 2026
• Early sales generated C$32k (~US$24k) validating market
• FDA 505(b)(2) pathway started; US launch targeted 2027
• Bayer-backed iodine project aims 35 M doses yearly

Summary

InvestorNews announced an InvestorTalk on March 31, 2026 at 9 AM EST featuring Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV:VM). Voyageur is advancing a vertically integrated strategy to produce barium and iodine contrast agents, highlighted by a 132,000‑tonne, 98.8% pure barium sulfate project slated for BFS completion in H2 2026. The company reported early sales of roughly C$32,000 (≈US$24,000) from Health Canada‑approved barium products and has initiated the FDA 505(b)(2) approval pathway for a 2027 U.S. launch. A US$2.35 million Bayer‑supported iodine project targets 35 million annual doses, underscoring potential high‑margin growth.

Pulse Analysis

The radiology contrast media market is experiencing a surge in demand as imaging procedures expand across hospitals and outpatient centers. Supply‑chain disruptions and reliance on imported raw materials have pressured pricing, prompting manufacturers to seek domestic sources. Voyageur’s vertically integrated model—controlling everything from raw‑material extraction at its Frances Creek barium sulfate deposit to final product formulation—directly addresses these challenges, promising tighter quality control and cost efficiencies that could reshape the Canadian and U.S. contrast‑agent landscape.

Recent milestones reinforce Voyageur’s growth trajectory. The company is completing two bankable feasibility studies for its barium and Bayer‑backed iodine projects, with the barium sulfate reserve of 132,000 tonnes (98.8% purity) on track for a second‑half‑2026 BFS finish. Early commercial traction is evident from roughly C$32,000 (about US$24,000) in sales of Health Canada‑approved barium contrast agents, providing real‑world pricing data. Simultaneously, Voyageur has entered the FDA’s 505(b)(2) pathway, aiming for a U.S. market entry by 2027, while the US$2.35 million Bayer partnership targets production of 35 million iodine doses per year, adding a high‑volume revenue stream.

For investors, Voyageur presents a compelling blend of regulatory progress, strategic financing, and market‑ready products. The dual‑track approach—securing Canadian approvals while pursuing U.S. clearance—reduces geographic risk and opens sizable revenue opportunities in the $5 billion North American contrast‑media market. If the company meets its BFS timelines and successfully scales production, it could transition from a development‑stage entity to a profitable, high‑margin manufacturer, attracting further partnership capital and potentially reshaping supply dynamics in radiology diagnostics.